EUVIMEDEUVIMED entdecken
Crossref

Impact of Selective Serotonin Reuptake Inhibitors on Bleeding Rates in HeartMate 3 Left Ventricular Assist Device Patients Not Taking Aspirin

Madeline Ganter iD, MaryAnn Bowyer, Emily Relic, Rachel Sickley, Mackenzie Warner, William L Baker iD, Ian B Hollis

Artificial Organs · 2025

DOI: 10.1111/aor.70078 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Artificial Organs, 2025. Verfasst von Madeline Ganter und 6 weiteren Autor:innen. Beteiligte Einrichtung: UNC Medical Center, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Heart-Assist Devices, Selective Serotonin Reuptake Inhibitors, Hemorrhage, Heart Failure. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Selective serotonin reuptake inhibitor (SSRI) and serotonin‐norepinephrine reuptake inhibitor (SNRI) therapy have been associated with increased bleeding risk in left ventricular assist device (LVAD) patients receiving warfarin and aspirin. In 2019, our institution stopped routinely prescribing aspirin to patients with a HeartMate 3 (HM3) LVAD.

Methods

This single‐center retrospective cohort study evaluates the risk of major bleeding with SSRI/SNRI use in HM3 LVAD patients not receiving aspirin. The primary outcome was the incidence of a major bleeding event, defined as an INTERMACS type 2, 3a, 3b, or 5 bleed, and was analyzed using a multivariable Cox proportional hazard regression model with age, gender, chronic kidney disease stage 3–5, angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker use, history of a gastrointestinal bleed, and warfarin time in therapeutic range as covariates.

Results

Of the included 101 patients, 60 (59%) received an SSRI/SNRI. A major bleeding event occurred in 11 (18%) patients in the SSRI/SNRI group and 6 (15%) patients in the non‐SSRI/SNRI group, which was not significantly different following multivariate adjustment (HR 1.04, 95% CI 0.32–3.37, p = 0.43).

Conclusions

Further studies in larger populations are needed to confirm the lack of association between SSRI/SNRI use and bleeding in HM3 LVAD patients not receiving aspirin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart-Assist DevicesSelective Serotonin Reuptake InhibitorsHemorrhageHeart FailureHumansFemaleMaleRetrospective StudiesMiddle AgedAspirinAgedRisk FactorsIncidence

Stichwörter der Autor:innen

HeartMate 3LVADSNRISSRIaspirinbleeding

Substanzen

Selective Serotonin Reuptake InhibitorsAspirin

Autor:innen und Institutionen

  • UNC Medical Center, Chapel Hill, North Carolina, USA.
  • University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
  • University of Cincinnati Medical Center, Cincinnati, Ohio, USA.
  • UConn School of Pharmacy, Storrs, Connecticut, USA.

ORCID-Profile: Madeline Ganter, William L Baker

Zitieren

APA

Ganter, M., Bowyer, M., Relic, E., Sickley, R., Warner, M., Baker, W. L., & Hollis, I. B. (2025). Impact of Selective Serotonin Reuptake Inhibitors on Bleeding Rates in HeartMate 3 Left Ventricular Assist Device Patients Not Taking Aspirin. Artificial Organs. https://doi.org/10.1111/aor.70078

Vancouver

Ganter M, Bowyer M, Relic E, Sickley R, Warner M, Baker WL, et al. Impact of Selective Serotonin Reuptake Inhibitors on Bleeding Rates in HeartMate 3 Left Ventricular Assist Device Patients Not Taking Aspirin. Artificial Organs. 2025. doi:10.1111/aor.70078

BibTeX
@article{Ganter2025,
  author = {Ganter, Madeline and Bowyer, MaryAnn and Relic, Emily and Sickley, Rachel and Warner, Mackenzie and Baker, William L and Hollis, Ian B},
  title = {Impact of Selective Serotonin Reuptake Inhibitors on Bleeding Rates in HeartMate 3 Left Ventricular Assist Device Patients Not Taking Aspirin},
  journal = {Artificial Organs},
  year = {2025},
  doi = {10.1111/aor.70078}
}
Kostenlos starten →